GWM
RETA

Geneos Wealth Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Geneos Wealth Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40
Closed -$3K – 3032
2020
Q3 		$3K Hold
40
– – ﹤0.01% 2362
2020
Q2 		$6K Hold
40
– – ﹤0.01% 2115
2020
Q1 		$5K Buy
+40
New +$7.72K ﹤0.01% 2067

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geneos Wealth Management's RETA Position: Q4 2020 in Review

Geneos Wealth Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 40 shares — an estimated $3K sold.

Geneos Wealth Management first reported a position in RETA in Q1 2020 and held it in 3 quarters. The position peaked at $6K in Q2 2020. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

  • Geneos Wealth Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 40 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $3K.
  • Geneos Wealth Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 3 quarters.
  • Geneos Wealth Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6K in Q2 2020.
  • 202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.